HOME >> BIOLOGY >> NEWS
Progenika Biopharma presents a biochip that guarantees safety in blood transfusions

agnosis (for diagnoses, prognoses and the prediction of and response to treatment of human diseases). So, in 2004 Progenika launched the LIPOchip on to the market, for the diagnosis of Family Hypercholesterolemia, the first biochip with the CE label and on sale since 2004. Progenika currently has 3 products that are at a development phase and which will finalise at the end of the year.


'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
4-Jul-2007


Page: 1 2

Related biology news :

1. Science survey ranks top Biopharma employers
2. FDA grants Accentia Biopharmaceuticals...
3. Accentia Biopharmaceuticals announces option agreement with Mayo
4. AutovaxID-C introduced by Accentia Biopharmaceuticals
5. Accentia Biopharmaceuticals acquires exclusive license
6. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
7. SNM presents awards on Capitol Hill
8. ESA presents the sharpest ever satellite map of Earth
9. New book presents neurobiology from an evolutionary perspective
10. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
11. Childrens Hospital and Research Center-Oakland presents a new maternal diet study

Post Your Comments:
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... , Oct 24, 2014 Research ... "Epigenetics Market by Product , Research Area & ... report to their offering. In this ... basis of products, research areas, and end users. The ... report are enzymes, instruments & consumables, kits, and reagents. ...
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2
Cached News: